Organization – Page 3

Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends

3 months ago talkbio0Tagged Bicycle, Financial cost, genentech, layoffs, Partnership, R&D, strategic realignment, Workforce reduction

Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment

Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats

3 months ago talkbio0Tagged Albert Bourla, Direct-to-Consumer, Drug Industry, drug price, Jr., Mehmet, Nation, negotiation, ounce, Pfizer, PhRMA, Policy, Pricing, Robert F. Kennedy, tariffs, Trump administration

Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA

Imunon Halts COVID-19 Vaccine Program, Seeks Partner Due to Financial Struggles

3 months ago talkbio0Tagged Cash Crunch, COVID19 (disease), deprioritization, financial results, IMNN-101, Imunon, Partnership, Vaccines

Imunon; COVID-19 vaccine; IMNN-101; deprioritization; cash crunch; partnership; financial results

Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million

3 months ago talkbio0Tagged Arrowhead, China, Familial chylomicronemia syndrome, Hypertriglyceridemia, milestone payments, Partnership, Plozasiran, RNA Interference, sanofi, Severe (severity modifier)

Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments

Moderna Wins UK Appeals Court in Covid-19 Patent Case Against Pfizer/BioNTech

3 months ago talkbio0Tagged appeal, BioNTech, court, COVID19 (disease), EP'949, infringement, Legal patent, legal victory, Moderna, Pfizer, UK, Vaccines

Moderna; Pfizer; BioNTech; UK Court of Appeal; COVID-19 vaccine; patent infringement; EP’949 patent; Comirnaty; legal victory

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

3 months ago talkbio0Tagged Antibodies, Biopharma, Clinical Trials, Dosage Forms, Japan, Kissei, Partnership, Thyroid associated opthalmopathies, Veligrotug, Viridian, VRDN-003

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal

Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital

3 months ago talkbio0Tagged Afimetoran, Autoimmune Diseases, BMS-986322, Clinical Development, Immunology, Investments, Myers, squibb

Bristol Myers Squibb; Bain Capital; immunology; autoimmune disorders; biotech spinout; afimetoran; BMS-986322; clinical development; investment; new company